PCSK9 as predictor for recurrent cardiovascular disease in familial hypercholesterolemia

被引：2
|
作者：
Reeskamp, Laurens F. [1 ]
Tromp, Tycho R. [1 ]
Hovingh, G. Kees [1 ]
机构：
[1] Univ Amsterdam, Amsterdam UMC, Dept Vasc Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
来源：
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2021年 / 28卷 / 03期
关键词：
CALCIFICATION; STATINS; EVENTS; RISK;
D O I：
10.1177/2047487319886140
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：270 / 271
页数：2
相关论文
共 50 条
  • [1] Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
    Huijgen, R.
    Fouchier, S. W.
    Denoun, M.
    Hutten, B. A.
    Vissers, M. N.
    Lambert, G.
    Kastelein, J. J. P.
    JOURNAL OF LIPID RESEARCH, 2012, 53 (05) : 979 - 983
  • [2] Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors
    Pecin, Ivan
    Hartgers, Merel L.
    Hovingh, G. Kees
    Dent, Ricardo
    Reiner, Zeljko
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2017, 24 (13) : 1383 - 1401
  • [3] How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana, Luis
    Plana, Nuria
    Perez-Calahorra, Sofia
    Ibarretxe, Daiana
    Lamiquiz-Moneo, Itziar
    Pedro-Botet, Juan
    Suarez-Tembra, Manuel
    Valdivielso, Pedro
    Ortega, Emilio
    Civeira, Fernando
    ATHEROSCLEROSIS, 2017, 262 : 107 - 112
  • [4] Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia
    Doi, Takahito
    Hori, Mika
    Harada-Shiba, Mariko
    Kataoka, Yu
    Onozuka, Daisuke
    Nishimura, Kunihiro
    Nishikawa, Ryo
    Tsuda, Kosuke
    Ogura, Masatsune
    Son, Cheol
    Miyamoto, Yoshihiro
    Noguchi, Teruo
    Shimokawa, Hiroaki
    Yasuda, Satoshi
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (04): : 1 - 11
  • [5] Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk
    Saavedra, Yascara G. Luna
    Dufour, Robert
    Baass, Alexis
    JOURNAL OF CLINICAL LIPIDOLOGY, 2015, 9 (06) : 786 - 793
  • [6] LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy
    Hamasaki, Masato
    Sakane, Naoki
    Hara, Kazuo
    Kotani, Kazuhiko
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2021, 35 (11)
  • [7] Healthy Individuals Carrying the PCSK9 p.R46L Variant and Familial Hypercholesterolemia Patients Carrying PCSK9 p.D374Y Exhibit Lower Plasma Concentrations of PCSK9
    Humphries, Steve E.
    Neely, R. Dermot G.
    Whittall, Roslyn A.
    Troutt, Jason S.
    Konrad, Robert J.
    Scartezini, Marileia
    Li, Ka Wah
    Cooper, Jackie A.
    Acharya, Jayshree
    Neil, Andrew
    CLINICAL CHEMISTRY, 2009, 55 (12) : 2153 - 2161
  • [8] Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience
    Alonso, Rodrigo
    Muniz-Grijalvo, Ovidio
    Luis Diaz-Diaz, Jose
    Zambon, Daniel
    de Andres, Raimundo
    Arroyo-Olivares, Raquel
    Fuentes-Jimenez, Francisco
    Sanchez Munoz-Torrero, Juan
    Cepeda, Jose
    Aguado, Rocio
    Alvarez-Banos, Pilar
    Casanas, Marta
    Dieguez, Marta
    Dolores Manas, Maria
    Rubio, Patricia
    Argueso, Rosa
    Arrieta, Francisco
    Gonzalez-Bustos, Pablo
    Perez-Isla, Leopoldo
    Mata, Pedro
    JOURNAL OF CLINICAL LIPIDOLOGY, 2021, 15 (04) : 584 - 592
  • [9] PCSK9: A link between air pollution and cardiovascular disease?
    Prochaska, Juergen H.
    Troebs, Sven-Oliver
    Wild, Philipp S.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2019, 26 (06) : 576 - 577
  • [10] Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease
    Wojcik, Cezary
    POSTGRADUATE MEDICINE, 2017, 129 (08) : 801 - 810
12345